-=Axon (AAXN) reported earnings on Thur 7 Nov 19 (a/h)

Axon beats by $0.02, beats on revs; raises FY19 revs guidance, reaffirms adj EBITDA guidance 

Reports Q3 (Sep) earnings of $0.28 per share, $0.02 better than the S&P Capital IQ Consensus of $0.26; revenues rose 24.8% year/year to $130.84 mln vs the $122.72 mln S&P Capital IQ Consensus; Adjusted EBITDA was a record $24 million

Co sees FY19 revs of $500-510 mln, from $485-495 mln vs. $489.38 mln S&P Capital IQ Consensus; reiterates expectations for annual Adjusted EBITDA of $80-85 million. Expects Adjusted EBITDA margin to improve sequentially in Q4 2019 driven by leverage on operating expenses, partially offset by gross margin pressure due to increased hardware mix. The expected strength of Axon Body 3 and TASER 7 cartridge shipments will result in an increased mix of lower margin hardware revenue in Q4 2019.